Planning consent has been granted for a £1 billion expansion of the London Cancer Hub in Sutton, paving the way for one of the UK’s most significant life sciences developments. The scheme will deliver around 1 million sq ft of new laboratory and research space, accelerating the growth of what is already a globally recognised centre for cancer research and innovation.

Led by Aviva Capital Partners and development manager Socius, the approved scheme will transform 12 acres into a high-density, research-focused campus supporting collaboration between scientists, clinicians, start-ups and major life sciences companies.

The new development is expected to create 3,000 high-skilled jobs in R&D, manufacturing and support services. Once fully realised, the wider London Cancer Hub district is projected to support 13,000 jobs and contribute £1.2 billion in Gross Value Added to the UK economy, according to analysis by the London Borough of Sutton.

Planning was approved by Sutton Council on World Cancer Day (4 February), underlining the site’s national significance. The hub already houses The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and the Innovation Gateway incubator for early-stage companies.

Sophie White, sector head of regeneration at Aviva Capital Partners, described the approval as a “landmark moment” for the project. “This development will deliver critical science infrastructure for the UK, helping the UK get ready for the future by creating an environment where innovation can flourish and lifesaving research can accelerate,” she said.

Designed by Gensler, the new district will target net zero carbon in operation and include affordable homes for around 220 key workers, alongside new public spaces to support wellbeing and collaboration. The project won the 2025 New London Architecture Award for Healthcare and Life Sciences.

The London Cancer Hub is identified in the Mayor of London’s Growth Plan as a key engine for frontier innovation, and is aligned with wider government ambitions to position the UK as a global leader in life sciences. Once complete, the campus is expected to draw international investment, support commercialisation of research, and strengthen the UK's capacity to respond to future health challenges.